Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > More info:
View:
Post by biorun on Mar 22, 2021 2:42pm

More info:

Small world here. very interesting post from wallst germany:


the (dermatological) world is a village! Zoe Draelos, who in a study attested that Sirona Biochem's active ingredient TFC-1067 is superior to hydroquinone in the treatment of dyschromias (pigmentation disorders), repeatedly appears with an interesting co-author in her publications in scientific media: Elizabeth T Makino, who in turn has been for years is looking for an effective alternative to hydroquinone under the Allergans brand Skinmedica (e.g. see https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025517/ or https://jddonline.com/articles/ dermatology / S1545961612P1478X…(Just for the critical questions why Allergan should be interested in a skin lightener ) She is now Director, Clinical Development Skincare at AbbVie, Abbvie is known to incorporate Allergan and Director, Clinical Development of Allergan. Overall, Ms. Draelos appears quite frequently in connection with Allergan. I read the interview with Geraldine again and I would be surprised if Allergan wasn't the company she meant in Min25 ff and that for anti wrinkle / anti aging is the one who supports here at an early stage .. 

Sirona Biochem | wallstreet-online.de

Comment by str8goods4achg on Mar 22, 2021 4:29pm
Good find... Sirona did the dance with Allergan for years... all us Longs thought a deal was going to be done with them... until it wasn't. That ended about 3-4 years ago?? I would be surprised if Howard did a second round with Allergan...unless it was too hard to turn down. $ can overcome historical issues! Personally, I think there are better potential partners now... speciifically in ...more  
Comment by forhandlaren on Mar 22, 2021 5:04pm
I think Alllergan could be a strategic mistake if an exclusive deal or head start for two years is on the table. The anti-wrinkle is a competitor to Botox with massive sales. Even with contract penalties Allergan can easily afford to put the compound in the freezer...
Comment by biorun on Mar 23, 2021 12:32pm
The foundational IP is proven and probable now. That changes to conversation, considerably. We need to be ready for pretty much anything at this point.  Nice place to be, finally.
Comment by skiboard09 on Mar 23, 2021 1:11pm
How much longer for trial results? How much longer for pet deal? how much longer for pending news on Wangbang front?   
Comment by pointer on Mar 23, 2021 2:24pm
This post has been removed in accordance with Community Policy
Comment by lscfa on Mar 23, 2021 2:37pm
.   Any day now..... feb 24/2021 - Our second clinical trial for TFC-1067, utilizing a higher dose, has been successfully completed and preliminary results have been received from Dermscan. We expect the final report within 4 weeks at which time we will review the results with our pharmaceutical partner ( see news Oct 2020 ). We anticipate being able to release a portion ...more  
Comment by skiboard09 on Mar 23, 2021 3:12pm
So they have the results. Now need to review with top 10 pharma before releasing full results?  So wonder how long this will be..... what can be released independent of partner?    
Comment by pointer on Mar 23, 2021 5:19pm
This post has been removed in accordance with Community Policy
Comment by pointer on Mar 22, 2021 5:43pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities